Shares of Talecris Biotherapeutics fell 6 percent in trade this sunrise after the association reported weaker monetary formula for the fourth quarter.
Revenue did conduct to surpass expectations, but benefit per share fell short of what analysts were anticipating.
Late Tuesday the Research Triangle Park company, the Triangles largest biotechnology company, reported that income fourth entertain was $390.1 million, down 2.8 percent from the same duration a year earlier.
Profit, after incompatible a one-time charge, was twenty-two cents per share. A year ago the association posted a distinction of twenty-eight cents per share. Expenses rose, together with higher costs to marketplace the medicines done from red blood plasma.
Talecris" products embody Gamunex, that is used to provide a sort of defence deficiency, and Prolastin, a diagnosis for genetic emphysema. The association employs about 2,200 people in the Triangle, and is expanding the large drug bureau in Clayton.
Its shares were trade at $22 this morning, down $1.24. Talecris shares fetched $19 when the association went open last fall.
Revenue for all of 2009 totaled $1.53 billion, up 11.6 percent from 2008. Profit for the year, together with a $48.8 million one-time benefit and a one-time $26.3 million charge, totaled $142.1 million contra $51.1 million in 2008.
No comments:
Post a Comment